Point-of-Care Urine Lipoarabinomannan Testing to Guide Tuberculosis Treatment Among Severely Ill Inpatients With Human Immunodeficiency Virus in Real-World Practice: A Multicenter Stepped Wedge Cluster-Randomized Trial From Ghana
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The lateral flow urine lipoarabinomannan assay, Determine TB LAM (Determine LAM), offers the potential for timely tuberculosis (TB) treatment among people with human immunodeficiency virus (PWH). METHODS: In this cluster-randomized trial, Determine LAM was made available with staff training with performance feedback at 3 hospitals in Ghana. Newly admitted PWH with a positive World Health Organization four-symptom screening for TB, severe illness, or advanced HIV were enrolled. The primary outcome was days from enrollment to TB treatment initiation. We also reported the proportion of patients with a TB diagnosis, initiating TB treatment, all-cause mortality, and Determine LAM uptake at 8 weeks. RESULTS: We enrolled 422 patients including 174 (41.2%) in the intervention group. The median CD4 count was 87 (interquartile range [IQR], 25-205) cells/μL, and 32.7% were on antiretroviral therapy. More patients were diagnosed with TB in the intervention compared with the control group: 59 (34.1%) versus 46 (18.7%) (P < .001). Time to TB treatment remained constant, but patients were more likely to initiate TB treatment (adjusted hazard ratio, 2.19 [95% CI, 1.60-3.00]) during the intervention. Of patients with a Determine LAM test available, 41 (25.3%) tested positive. Of those, 19 (46.3%) initiated TB treatment. Overall, 118 patients had died (28.2%) at 8 weeks of follow-up. CONCLUSIONS: The Determine LAM intervention in real-world practice increased TB diagnosis and the probability of TB treatment but did not reduce time to treatment initiation. Despite high uptake, only half of the LAM-positive patients initiated TB treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This design allows for the gradual rollout of the intervention, facilitating logistical management and ensuring that all clusters eventually receive the intervention, while also enabling a rigorous evaluation of its effectiveness”
From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Each hospital had a control period for a minimum of 22 weeks before transitioning to the intervention period for a minimum of 20 weeks. Enrollment was ceased for 28 weeks due to COVID-19 restriction”
From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“3”
From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“Cluster randomization was undertaken by an impartial biostatistician. Each hospital started with a control period and then randomly and sequentially switched over to the intervention period. The randomization order was open-labeled”
From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [68]
The cited source says what the claim attributes to it.
In the citing paper
“3”
From Applications and implementation considerations for stepped-wedge designs in sub-Saharan Africa: a systematic review (2026) · cites this paper as [68]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting
Hemming, K., Haines, T. P., Chilton, P. J., Girling, A. J., & Lilford, R. J. (2015) · BMJ · doi:10.1136/bmj.h391 · Cited by 1,410
A systematic review of delay in the diagnosis and treatment of tuberculosis
Storla, D. G., Yimer, S., & Bjune, G. A. (2008) · BMC Public Health · doi:10.1186/1471-2458-8-15 · Cited by 1,018
Johnson, M. J., & May, C. R. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008592 · Cited by 513
Hemming, K., Taljaard, M., McKenzie, J. E., Hooper, R., Copas, A., Thompson, J. A., Dixon-Woods, M., Aldcroft, A., Doussau, A., Grayling, M., et al. (2018) · BMJ · doi:10.1136/bmj.k1614 · Cited by 475
Gupta, R. K., Lucas, S. B., Fielding, K. L., & Lawn, S. D. (2015) · AIDS · doi:10.1097/qad.0000000000000802 · Cited by 371
Peter, J. G., Zijenah, L. S., Chanda, D., Clowes, P., Lesosky, M., Gina, P., Mehta, N., Calligaro, G., Lombard, C. J., Kadzirange, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01092-2 · Cited by 276
Gupta-Wright, A., Corbett, E. L., van Oosterhout, J. J., Wilson, D., Grint, D., Alufandika-Moyo, M., Peters, J. A., Chiume, L., Flach, C., Lawn, S. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31267-4 · Cited by 213
Bjerrum, S., Schiller, I., Dendukuri, N., Kohli, M., Nathavitharana, R. R., Zwerling, A. A., Denkinger, C. M., Steingart, K. R., & Shah, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011420.pub3 · Cited by 186
Self-citation
Research works printed but not linked: 3
- World Health Organization (WHO), 2015, The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy update
- Bonsu, 2018, Standard operating procedures for systematic screening for active TB at health facility and different settings
- World Health Organization (WHO), 2017, Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy
Cited by
Tuberculosis and HIV coinfection: Progress and challenges towards reducing incidence and mortality
Sossen, B., Kubjane, M., & Meintjes, G. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.107876 · Cited by 95
Freitag, B., Sultanli, A., Grilli, M., Weber, S. F., Gaeddert, M., Abdullahi, O. A., Denkinger, C. M., & Gupta‐Wright, A. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103251 · Cited by 16
Åhsberg, J., Tersbøl, B. P., Puplampu, P., Kwashie, A., Commey, J. O. O., Adusi-Poku, Y., Moseholm, E., Andersen, Å. B., Kenu, E., Lartey, M. Y., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1271763 · Cited by 7
Self-citationLow tuberculosis treatment initiation after positive tuberculosis lipoarabinomannan results
Gils, T., Madonsela, T., Kamele, M., Ayakaka, I., van Heerden, A. C., Vlieghe, E., Bresser, M., Decroo, T., Lynen, L., Reither, K., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00182-2024 · Cited by 4
Bjerrum, S., Yang, B., Åhsberg, J., Olbrich, L., Damkjær, M. W., Nathavitharana, R. R., Broger, T., Olaru, I. D., Sweetser, B., Poore, H., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016070.pub2 · Cited by 4
Self-citationCossa, M., Ndege, R. C., Meggi, B., Mangu, C., Leukes, V., Sabi, I., Khosa, C., Kivuma, B., Nguenha, D., Rieß, F., et al. (2026) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(26)00133-7 · Cited by 2
Barclay-Korboi, Y. M., Adeel, A., Ajami, I., Dickson, F. H., Wachekwa, I., Vaye, N. A. F., & Levitz, S. M. (2025) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0013008 · Cited by 2
“In a cluster randomized trial performed in Ghana, lipoarabinomannan testing reduced the time to diagnosis of tuberculosis and initiation of antituberculosis therapy [28].”
Urine-based assays for inpatients with HIV-associated tuberculosis in rural South Africa
Mntonintshi, M., Sossen, B., Bookholane, H., Lifson, A., Africa, L., Goliath, R. T., Wearne, N., Parrish, A., & Meintjes, G. (2025) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v26i1.1705 · Cited by 1
Musa, Z. A., Akinsolu, F. T., Salako, A. O., Abodunrin, O. R., Ola, O. M., & Ezechi, O. C. (2026) · Frontiers in Epidemiology · doi:10.3389/fepid.2026.1529289
Diagnostic and prognostic utility of urine LF-LAM assay for tuberculosis detection in advanced HIV
Zafar, A., Akhtar, N., Virk, S. T., Virk, K. A., Umair, M. M., & Saghir, H. (2025) · Infectious Diseases Journal of Pakistan · doi:10.61529/idjp.v34i1.368
Makgoka, T. R., de Villiers, M., & Zyl, D. G. V. (2025) · South African Medical Journal · doi:10.7196/samj.2025.v115i2.2143
“[9,11,14] In a study by Ahsberg et al ., [23] where urine LAM was added to routine testing, 50% of patients with a positive urine LAM were started on TB treatment.”
Moshi, L., Bakari, H. M., Mbishi, J. V., Ally, Z. M., Mbwana, M. S., Ally, H. M., Musoke, R., Salim, S. M., Karia, M. F., Karia, L. F., et al. (2025) · World Journal of Virology · doi:10.5501/wjv.v14.i3.107214
Åhsberg, J., Bjerrum, S., Asare, P. P. A., Osei-Wusu, S., Afum, T., Sorvor, F. K. B., Adusi-Poku, Y., Lartey, M. Y., Yeboah‐Manu, D., Opintan, J. A., et al. (2025) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2025.108254
Self-citationRole of recruitment bias in stepped-wedge cluster randomised controlled trials: a systematic review
Yakimova, A., Wiggins, F., Kanaan, M. N., Keding, A., & Torgerson, D. J. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-096281
Abdulwahhab, A. H., Mahdi, M. S., al-Hameed, B. J. A., & Suood, A. M. (2025) · Journal of Scientific Research in Science /Journal of Scientific Research in Science · doi:10.21608/jsrs.2025.420831.1225
Dele-Olowu, S. K. M., Baatiema, L., Vroom, F. B. D.-C., Udofia, E. A., de Witte, L., Yawson, A. E., & Balen, J. (2026) · BMJ Public Health · doi:10.1136/bmjph-2025-003704
“17 21 28–36 The Lancet Commission on Diagnostics further emphasises that the lack of visibility and priority for diagnostics in many LMICs is the root cause of limited access to essential diagnostic tests.”
Metadata
- Authors
- Åhsberg, J., Puplampu, P., Kwashie, A., Commey, J. O., Ganu, V. J., Omari, M. A., Adusi-Poku, Y., Andersen, Å. B., Kenu, E., Lartey, M., Johansen, I. S., & Bjerrum, S.
- Affiliations
- Statens Serum Institut (DK)
- University of Ghana (GH)
- Department of Medicine, Tema General Hospital , Tema, Ghana
- Ghana Health Service (GH)
- Korle Bu Teaching Hospital (GH)
- Copenhagen University Hospital (DK)
- Research Center of Infectious Diseases, Department of Clinical Research, University of Southern Denmark , Odense, Denmark
- University of Southern Denmark (DK)
- Corresponding author
- Åhsberg, Johanna
- Bjerrum, Stephanie
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-05-26
- Volume
- 77
- Issue
- 8
- Pages
- 1185-1193
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4378349612
- Cited by
- 14
- References
- 29
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 2
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Funders
- Læge Agnethe Løvgreens legat
- Torben og Alice Frimodts fond
- A.P. Møller fonden
- University of Southern Denmark
- Odense University Hospital
- Strategic Research Council
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- tuberculosis, HIV, lipoarabinomannan, point-of-care testing, TB treatment initiation, tuberculosis diagnosis, severe illness, hospitalized patients, all-cause mortality, employee training, performance feedback, Ghana
- MeSH terms
- Point-of-Care Testing, Adult, Antitubercular Agents, Female, Ghana, Humans, Inpatients, Lipopolysaccharides, Male, Middle Aged, Tuberculosis, HIV Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.